)

LB Pharmaceuticals (LBRX) investor relations material
LB Pharmaceuticals Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Clinical development and pipeline
Advancing LB-102, a novel derivative of amisulpride, for neuropsychiatric disorders including schizophrenia (SCZ), bipolar depression (BPD), and major depressive disorder (MDD).
Phase 2 SCZ trial showed statistically significant benefit versus placebo at all doses, with robust effect sizes and improvements in cognition.
Phase 3 SCZ trial is planned for initiation in 1Q 2026, with topline data expected in 2H 2027; a Phase 2 BPD trial is also planned with topline data anticipated in 1Q 2028.
FDA feedback suggests potential for SCZ approval with one successful Phase 3 trial, streamlining the regulatory path.
Additional opportunities for indication expansion into MDD and development of long-acting injectable (LAI) formulations.
Efficacy and safety profile
LB-102 demonstrated clinically meaningful PANSS reductions and significant cognitive improvements in SCZ patients.
Safety profile is differentiated by low rates of extrapyramidal symptoms (EPS), negligible sedation, and minimal QTc prolongation.
Most adverse events were mild or moderate, with low rates of discontinuation and serious adverse events.
Weight gain was modest and no concerning metabolic signals were observed.
LB-102 retains the binding profile of amisulpride with improved blood-brain barrier permeability and potency.
Market opportunity and competitive landscape
Multibillion-dollar sales potential for LB-102 across SCZ, BPD, and MDD, with strong IP protection expected through 2041.
Branded antipsychotics in the U.S. generated ~$12B in 2024, with Vraylar, Abilify, Rexulti, and Caplyta accounting for ~60% of sales.
BPD and MDD represent large, underserved markets with substantial unmet needs for better efficacy, safety, and cognitive outcomes.
LB-102's differentiated profile positions it as a potential class leader, especially as few branded agents are expected at BPD launch.
Development path validated by successful precedents such as Vraylar and Caplyta.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage